Novel Molecular Imaging of Atherosclerosis With Gallium-68-Labeled Apolipoprotein A-I Mimetic Peptide and Positron Emission Tomography

Kawachi, Emi; Uehara, Yoshio; Hasegawa, Koki; Yahiro, Eiji; Andò, Sebastiano; Wada, Yasuhiro; Yano, Takeru; Nishikawa, Hiroaki; Shiomi, Masashi; Miura, Shin; Watanabe, Yasuyoshi; Saku, Keijiro

doi:10.1253/circj.cj-12-0736

Cited by 29 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FAMP was modified so it could be radiolabeled with gallium-68 for noninvasive positron emission tomography (PET) in a rabbit model of familial hypercholesterolemia that spontaneously develops myocardial infarction (WHHL-MI) [32*]. The radiolabeled FAMP was dramatically taken up by atherosclerotic tissues in the blood vessels and aorta of WHHL-MI rabbits but not in control rabbits [32*].…”

Section: Other Apolipoprotein-mimeticsmentioning

confidence: 99%

Apolipoprotein A-I mimetics

Reddy

Navab²,

Anantharamaiah

et al. 2014

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of Review To summarize recent publications in the field of apolipoprotein mimetics. Recent Findings Apolipoprotein mimetic peptides continue to show efficacy in a number of animal models of disease and demonstrate properties that make them attractive as potential therapeutic agents. A number of new apolipoprotein mimetics have been described recently. A major site of action of apolipoprotein mimetic peptides was found to be in the small intestine where they decrease the levels of pro-inflammatory bioactive lipids. A major problem related to the use of apolipoprotein mimetic peptides is their cost, particularly those that need to be generated by solid phase synthesis with chemical addition of end blocking groups. Novel approaches to apolipoprotein mimetic therapy have emerged recently that show promise in overcoming these barriers. Summary Despite the recent failure of therapies designed to raise HDL-cholesterol in humans, an approach to therapy using mimetics of HDL and its components continues to show promise.

show abstract

Section: Other Apolipoprotein-mimeticsmentioning

confidence: 99%

Apolipoprotein A-I mimetics

Reddy

Navab²,

Anantharamaiah

et al. 2014

Current Opinion in Lipidology

View full text Add to dashboard Cite

show abstract

“…Thus, atherosclerotic plaques incorporate 68 Ga-DOTA-FAMP at a high rate, generating impressive PET images of an aortic plaque in vivo. 41) Several fundamental experiments have shown that the administration of ApoA-I or artificial HDL is a novel therapeutic strategy for the treatment of atherosclerosis. CSL-111 is a reconstituted-HDL comprising ApoA-I isolated from human plasma and phosphatidylcholine derived from soybean.…”

Section: Apoa-i Mimetic Peptide: Apl180 (L-4f)mentioning

confidence: 99%

High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases

Ikenaga

Higaki

Saku

et al. 2016

JAT

Self Cite

View full text Add to dashboard Cite

Clinical trials and epidemiological studies have revealed a negative correlation between serum highdensity lipoprotein (HDL) cholesterol levels and the risk of cardiovascular events. Currently, statin treatment is the standard therapy for cardiovascular diseases, reducing plasma low-density lipoprotein (LDL) cholesterol levels. However, more than half of the patients have not been able to receive the beneficial effects of this treatment. The reverse cholesterol transport pathway has several potential anti-atherogenic properties. An important approach to HDL-targeted therapy is the optimization of HDL cholesterol levels and function in the blood to enhance the removal of circulating cholesterol and to prevent or mitigate inflammation that causes atherosclerosis. Cholesteryl ester transfer protein inhibitors increase HDL cholesterol levels in humans, but whether they reduce the risk of atherosclerotic diseases is unknown. HDL therapies using HDL mimetics, including reconstituted HDL, apolipoprotein (Apo) A-IMilano, ApoA-I mimetic peptides, or full-length ApoA-I, are highly effective in animal models. In particular, the Fukuoka University ApoA-I-mimetic peptide (FAMP) effectively removes cholesterol via the ABCA1 transporter and acts as an anti-atherosclerotic agent by enhancing the biological functions of HDL without elevating HDL cholesterol levels. Our literature review suggests that HDL mimetics have significant atheroprotective potential and are a therapeutic tool for atherosclerotic diseases. J Atheroscler Thromb, 2016; 23: 385-394.

show abstract

“…Thus, atherosclerotic plaques incorporate 68 Ga-DOTA-FAMP at a high rate, generating impressive PET images of an aortic plaque in vivo. 66 Uchida et al have also investigated plaque characteristics using color fluorescent microscopy and shown the fluorescent characteristics of HDL deposits with plaque formation, but not in the advanced stage of plaque in the human coronary arterial wall. 67 We believe that HDL-targeted therapy, including the use of FAMP, has tremendous atheroprotective potential and likely represents a new therapeutic tool for treating atherosclerotic cardiovascular disease.…”

Section: Apoa-i Milanomentioning

confidence: 99%